Corticolimbic Dopamine Neurotransmission Is Temporally Dissociated from the Cognitive and Locomotor Effects of Phencyclidine
Open Access
- 15 July 1998
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 18 (14), 5545-5554
- https://doi.org/10.1523/jneurosci.18-14-05545.1998
Abstract
The behavioral syndrome produced by phencyclidine (PCP) and its analog ketamine represents a pharmacological model for some aspects of schizophrenia. Despite the multifaceted properties of these drugs, the main mechanism for their psychotomimetic and cognitive-impairing effects has been thought heretofore to involve the corticolimbic dopamine system. The present study examined the temporal relationship between alterations in corticolimbic dopamine and glutamate neurotransmission and two dopamine-dependent behavioral effects of PCP in the rodent that have relevance to the clinical phenomenology, namely, impairment of working memory, which is used to model the frontal lobe deficits associated with schizophrenia, and hyperlocomotion, which is used as a predictor of the propensity of a drug to elicit or exacerbate psychosis. PCP increased dopamine and glutamate efflux in the prefrontal cortex and nucleus accumbens, as measured by microdialysis. The increase in dopamine in both regions remained elevated well above baseline 2.5 hr after the injection, at which time the experiment was terminated. However, locomotor activity returned to baseline in <2 hr after injection. Furthermore, impaired performance in a discrete trial delayed alternation task, a rodent working memory task, was only evident up to 60 min after PCP injection; animals tested 80 min after injection, when cortical dopamine release was elevated at 300% of baseline, did not exhibit impaired performance. These findings indicate that activation of dopamine neurotransmission is not sufficient to sustain PCP-induced locomotion and impairment of working memory. Thus, effects of PCP, including a glutamatergic hyperstimulation, may be necessary to account for the psychotomimetic and cognitive-impairing effects of this drug.This publication has 82 references indexed in Scilit:
- Resistance of the Dopamine D2L Receptor to Desensitization Accompanies the Up-Regulation of Receptors on to the Surface of Sf9 CellsEndocrinology, 1997
- Concurrent locomotor stimulation and decrease in dopamine release in rats and mice after treatment with the competitive NMDA receptor antagonists D-CPPene and CGS 19755Journal of Neural Transmission, 1996
- Effects of d-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the ratBehavioural Brain Research, 1995
- Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in ratsJournal of Neural Transmission, 1995
- Phencyclidine and the midbrain dopamine system: Electrophysiology and behaviorNeurotoxicology and Teratology, 1994
- Characterization of two central AMPA-preferring receptors having distinct location, function and pharmacologyNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1994
- Neuropharmacology of Phencyclidine: Basic Mechanisms and Therapeutic PotentialAnnual Review of Pharmacology and Toxicology, 1990
- The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted miceJournal of Neural Transmission, 1989
- Effects of N-allylnormetazocine (skf 10,047), phencyclidine, and other psychomotor stimulants in the rat following 6-hydroxydopamine lesion of the ventral tegmental areaNeuropharmacology, 1986
- The Effect of 1-Arylcyclohexylamine (Sernyl) on Twelve Normal VolunteersJournal of Mental Science, 1960